You are a passage reranking assistant. Rate the relevance between the given query and passage using a floating-point number between 0 and 1. The query includes a query ID (qid) and the query content (query). Each passage includes a passage ID (pid) and the passage content (passage). 

- A score close to **1.00** means the passage is **highly relevant** to the query.
- A score close to **0.00** means the passage is **not relevant** to the query.
- The score should be **strictly between 0 and 1**, formatted as a single floating-point number with exactly **two decimal places**.

Output only a single number between 0.00 and 1.00, rounded to two decimal places as the final score, with no explanation.

    Input: 'qid':1101259
'query':docetaxel is also known as
'pid':6112509
'passage':email. MNT featured. Xtandi (enzalutamide) has been approved for men with metastatic castration-resistant prostate cancer that has recurred or spread, regardless of whether patients received medical or surgical therapy to reduce testosterone levels, the US Food and Drug Administration (FDA) announced.tandi is the latest treatment for this disease to demonstrate its ability to extend a patient's life.. FDA scientists evaluated Xtandi's efficacy and safety by assessing data from a clinical trial involving 1,199 men with metastatic castration-resistant prostate cancer who had previously received docetaxel.
    Output:
    